Posted: 24 October 2025
Immuron has officially launched PROIBS®, a new product designed to relieve symptoms of medically diagnosed Irritable Bowel Syndrome (IBS), into the Australian market. The biopharmaceutical company confirmed that pharmacy orders had already been received ahead of the end-of-the-year season, when IBS symptom triggers are at their highest.
Chief Commercial Officer Flavio Palumbo said the company had worked hard to bring the product to market quickly. “It has been a lot of work to develop an accelerated launch for PROIBS® in Australia, right in time for the peak festive season where IBS symptom triggers are highest,” he said. “We believe once Australian consumers try PROIBS®, they will love it.”
The launch will initially focus on online and selected pharmacies, supported by a nationwide awareness and digital marketing campaign. PROIBS® joins Immuron’s growing digestive health portfolio, alongside its well-known Travelan® brand, expanding the company’s range of premium consumer health products recommended by pharmacists.
IBS is a common digestive disorder affecting around three in ten Australians, with symptoms including abdominal discomfort, bloating, and irregular bowel habits. Women are more frequently affected than men. Australia’s “Digestives & Intestinal Remedies” market—of which IBS treatments form a major segment—is valued at approximately AU$221 million in 2025, with an expected annual growth rate of 3.28%.
A usability study of more than 1,000 users found that 94% reported PROIBS® was helpful, 91% experienced improved daily life, and 98% would recommend it to others.
Find out more here.
